Akums Drugs adj. net profit rises 16% YoY to Rs 66.7 crore in Q2FY25
Akums Drugs and Pharmaceutical, the Delhi-based contract development and manufacturing organisation (CDMO) reported an adjusted net profit of Rs ₹66.7 crore, a 16% year-on-year (YoY) increase from the previous quarter led operational efficiency.
Revenue declined 11.9% YoY to ₹1046.6 crore due to lower active pharmaceutical ingredient (API) prices and fluctuating demand.
Adjusted EBITDA recorded at ₹1,347 million, a 28% drop over the previous quarter, while the company’s adjusted EBITDA margin of 12.9%.
Akums said it remains optimistic that it will stabilize as it expands its footprint and its cash surplus position remains robust at ₹340.6 crore will be instrumental in supporting further investment in R&D and expanding production and business capabilities.
“Short term volatility apart, we continue to see strong secular demand for outsourced drug development and manufacturing," said Sanjeev Jain, managing director.
Stock Trading
A2Z of Stock Trading — Online Stock Trading Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Stock Markets Made Easy
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading
By — Rohit Srivastava, Founder- Indiacharts.com
Stock Trading
RSI Made Easy: RSI Trading Course
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Cryptocurrency Made Easy: Cryptocurrency Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Options Trading Made Easy: Options
